Two-Drug immune combo shows promise for advanced kidney cancer

This study tested a combination of two immunotherapy drugs—high-dose interleukin-2 (IL-2) and pembrolizumab (Keytruda)—in 27 people with metastatic kidney cancer. The goal was to see if the pair could shrink tumors better than either drug alone. Participants received both drugs in a coordinated schedule, and researchers measured how many had their tumors shrink or disappear. While the treatment aims to control the disease, it is not a cure, as ongoing management is typically needed.